Botulinum toxin A for the treatment of cervical dystonia

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 9, 2004, Pages 2017-2024

  Zesiewicz, Theresa A ^a,b   Stamey, William ^b   Sullivan, Kelly L ^a,b   Hauser, Robert A ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Botox; Botulinum toxin A; Cervical dystonia; Dysport

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; CHLOROQUINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; GENTAMICIN; HYDROXYCHLOROQUINE; KANAMYCIN; PENICILLAMINE; PLACEBO; SODIUM CHLORIDE; STREPTOMYCIN; TOXIN ANTIBODY; TRIHEXYPHENIDYL;

ACETYLCHOLINE RELEASE; ANALGESIA; ANTIBODY PRODUCTION; ARTICLE; BRACHIAL PLEXUS NEUROPATHY; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DYSPHAGIA; DYSPHONIA; DYSPNEA; DYSTONIA; EATON LAMBERT SYNDROME; EUROPE; EXPERIENCE; FATIGUE; FEVER; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; INHIBITION KINETICS; INJECTION PAIN; IRELAND; LARYNX DISORDER; LETHARGY; MALAISE; MEDICAL ERROR; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NECK MUSCLE; NECROTIZING FASCIITIS; NEUROLOGIC DISEASE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; POLYRADICULITIS; RESPIRATORY TRACT INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; XEROSTOMIA;

ADULT; ANTIBODIES; BOTULINUM TOXIN TYPE A; CONTROLLED CLINICAL TRIALS; HUMANS; TORTICOLLIS;

EID: 4544377100     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.2017     Document Type: Article

References (80)

1. JANKOVIC J, SCHWARTZ K: Botulinum toxin injections for cervical dystonia. Neurology (1990) 40:277-280.
2. DAUER WT, BURKE RE, GREENE P, FAHN S: Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 121:547-560.
3. JANKOVIC J, LEDER S, WARNER D, SCHWARTZ K: Cervical dystonia: clinical findings and associated movement disorders. Neurology (1991) 41:1088-1091.
4. CHAN J, BRIN MF, EAHN S: Idiopathic cervical dystonia: clinical characteristics. Mov. Disord. (1991) 6:119-126.
5. TSUI JK, STEOSSL AJ, EISEN A et al.: Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 2(8501):245-247.
6. OVERVIEW A: Idiopathic cervical dystonia: an overview. Neurology (2000) 55(12 Suppl. 5):S2-S8.
7. SORENSEN BF, HAMBY WB: Spasmodic torticollis: results in 71 surgically treated patients. Neurology (1966) 16:867-878.
8. GELB DJ, LOWENSTEIN DH, AMINOFF MJ: Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology (1989) 39:80-84.
9. POEWE W, SCHELOSKY L, KLEEDORFER B et al.: Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients. J. Neurol. (1992) 239:21-25.
10. SCOTT AB: Botulinum toxin injection of eye muscles to correct strabismus. Trans. Am. Ophthalmol. Soc. (1981) 79:734-770.
11. SCOTT AB: Injection treatment of endocrine orbital myopathy. Doc. Ophthalmol. (1984) 58:141-145.
12. SCOTT AB, KRAFT SP: Botulinum toxin injection in the management of lateral rectus paralysis. Ophthalmology (1985) 92:676-683.
13. MAURIELO JA: Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology (1985) 35:1499-1500.
14. SCOTT AB, KENNEDY RA, STUBBS HA: Botulinum toxin injection as a treatment for blepharospasm. Arch. Ophthalmol. (1985) 103:347-350.
15. TSUI JK, EISEN A, MAKE E et al.: A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J. Neurol. (1985) 12:314-316.
16. BRASHEAR A, TRUONG B, CHARLES D et al.: A randomized, double-blind, placebo-controlled study of intramuscular BOTOX for the treatment of cervical dystonia. Mov. Disord. (1988) 13(Suppl. 2):276.
17. COMELLA CL, JANKOVIC J, BRIN MF: Use of botulinum of toxin type A in the treatment of cervical dystonia. Neurology (2000) 55(Suppl. 5):S15-S21.
18. LU CS, CHEN RS, TSAI CH: Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia. J. Formos. Med. Assoc. (1995) 94:189-192.
19. LORENTZ IT, SUBRAMANIAN SS, YIANNIKAS C: Treatment of idiopathic spasmodic torticollis with botulinum A: a double-blind study on twenty-three patients. Mov. Disord. (1991) 6:145-150.
20. GREENE P, KANG U, FAHN S et al.: Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 40:1213-1218.
21. BLACKIE JD, LEES AJ: Botulinum toxin treatment in spasmodic torticollis. J. Neurol. Neurosurg. Psychiatry (1990) 53:640-643.
22. MOORE AP, BLUMHARDT LD: A double blind trial of botulinum toxin 'A' in torticollis, with one year follow up. J. Neurol. Neurosurg. Psych. (1991) 54:813-816.
23. POEWE W, DEUSCHL G, NEBE A et al.: What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J. Neurol. Neurosurg. Psychiatry (1998) 64:13-17.
24. BRANS JW, KINDEBOOM R, SNOEK JW et al.: Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology (1996) 46:1066-1072.
25. BORODIC GE, JOSEPH M, FAY L et al.: Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck (1990) 12:392-399.
26. ADLER CH, KUMAR R: Pharmacological and surgical options for the treatment of cervical dystonia. Neurology (2000) 55:S9-S14.
27. ANDERSON TJ, RIVEST J, STELL R et al.: Botulinum toxin treatment of spasmodic torticollis. J. R. Soc. Med. (1992) 85:524-529.
28. JANKOVIC J, ORMAN J: Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology (1987) 37:616-623.
29. JANKOVIC J, SCHWARTZ K, DONOVAN DT: Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry (1990) 53:633-639.
30. NAUMANN M, YAKOVLEFF A, DURIF F: Botox Cervical Dystonia Prospective Study Group. A randomized, double-masked crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J. Neurol. (2002) 249(1):57-63.
31. RACETTE BA, MCGEE-MINNICH L, PERLMUTTER JS: Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin. Neuropharmacol. (1999) 22(6):337-339.
32. PHYSICIANS' DESK REFERENCE: 58th edn. Thompson PDR, Montvale, NJ, USA (2004).
33. HUANG W, FOSTER JA, ROGACHEFSKY AS: Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. (2000) 43:249-259.
34. SCHANTZ EJ, JAUTTER DA: Standardized assay for Clostridium botulinum toxins. J. Assoc. Anal. Chem. (1978) 61:96-99.
35. SCHANTZ EJ, JOHNSON EA: Dose standardization of botulinum toxin. Lancet (1990) 335:421.
36. TSUI JKC: Botulin toxin as a therapeutic agent. Pharmacol. Ther. (1996) 72:13-24.
37. BENTIVOGLIO, R, ALBANESE A: Botulinum toxin in motor disorders. Curr. Opin. Neurol. (1999) 12:447-456.
38. PEARCE LB, BORODIC GE, JOHNSON ET et al.: The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon (1995) 33:217-227.
39. COFFIELD JA, CONSIDINE RV, SIMPSON LL: The site and mechanism of action of botulinum neurotoxin. In: Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds). Marcel Dekker Inc, New York, USA (1993):3-13.
40. SCHIAVO G, ROSSETTO O, BENFENATI F et al.: Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann. NY Acad. Sci. (1994) 710:65-75.
41. Allergan, Inc: Botox® (botulinum toxin Type A Neurotoxin Complex) package insert. Allergan, Inc, Irvin, CA, USA (2004).
42. GARTLAN MG, HOFFMAN HT: Crystalline preparation of botulinum type A (Botox): degradation impotency with storage. Otolaryngol. Head Neck Surg. (1993) 108:135-140.
43. KLEIN AW: Dilution and storage of botulinum toxin. Dermatol. Surg. (1998) 24:1179.
44. WISSEL J, KANOVSKY P, RUZICKA E et al.: Efficacy and safety of a standardized 500 unit dose of Dysport (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomized, double-blind, placebo-controlled parallel group study. J. Neurol. (2001) 248:1073-1078.
45. COMELLA CL, BUCHMAN AS, TANNER CM et al.: Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology (1992) 42:878-882.
46. STELL R, THOMPSON PD, MARSDEN CD: Botulinum toxin in torticollis. Neurology (1989) 39:1403-1404.
47. MÜNCHAU A, FILIPOVIC SR, OESTER-BARKEY A et al.: Spontaneously changing muscular activation pattern in patients with cervical dystonia. Mov. Disord. (2001) 16:1091-1097.
48. JANKOVIC J, BRIN M: Botulinum toxin: historical perspective and potential new indications. Muscle Nerve (1997) 20(Suppl. 6):S129-S145.
49. ROLLNIK JD, MATZKE, M, WOHLFARTH K et al.: Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open-label study. Eur. Neurol. (2000) 43:9-12.
50. ODERGRAN T, HJALTASON H, KAAKKOLA S et al.: A double-blind, randomized, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry (1998) 64:6-12.
51. NOVIS SA, DE MATOX JP, DE ROSSO AL: Botulinum toxin in blepharospasm, in hemifacial spasm, and in cervical dystonia: Results in 33 patients. Arg. Neuropsiquiatr. (1995) 53:403-410.
52. BRASHEAR A, CULLIS P, MOLHO E et al.: Cervical Dystonia Severity Scale (CDSS) reliability study. Mov. Disord. (1998) 13(Suppl. 2):275.
53. JANKOVIC J, SCHWARTZ K: Clinical correlates of response to botulinum toxin injections. Arch. Neurol. (1991) 48:1253-1256.
54. JANKOVIC J: Medical therapy and botulinum toxin in dystonia. In: Dystonia 3: Advances in Neurology. Fahn S, Marsden CD, DeLong M (Eds). Lippincott Raven Publishers, Philadelphia, USA (1998):169-183.
55. JANKOVIC J, ORMAN J: Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology (1987) 37(4):616-623.
56. ELSTON J, RUSSELL RW: Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br. Med. J. (1985) 290:1857-1859.
57. PICKETT AM, HAMBLETON P: Dose standardization of botulinum toxin. Lancet (1994) 344:474-475.
58. BORODIC GE: Therapeutic botulinum toxin. Lancet (1994) 344:1370.
59. SESARDIC D, DAS R, CORBEL MJ: Botulinum toxin. J. R. Soc. Med. (1994) 87:307.
60. RANOUX D, GURY C, FONDARAI J et al.: Respective potencies of Botox and Dysport: a double-blind, randomized, crossover study in cervical dystonia. J. Neurol. Neurosurg. Psychiatry (2002) 72(4):459-462.
61. JANKOVIC J, VUONG KD, AHSAN J: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology (2003) 60:1186-1188.
62. GOESCHEL H, WOHLFAHRT K, FREVERT J et al.: Botulinum A toxin: neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp. Neurol. (1997) 147:96-102.
63. DRESSLER D, DIRNBERGER G: Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur. Neurol. (2001) 45:257-260.
64. COMELLA C, JANKOVIC J, DAGGETT S, MORDAUNT J, BRIN M: Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia. Neurology (2004) 62:A511.
65. GREENE P, FAHN S, DIAMOND B: Development of resistance to botulinum toxin type A in patients to botulinum toxin type A in patients with torticollis. Mov. Disord. (1994) 9:213-217.
66. GONCALVES MR, BARBOSA ER, ZAMBON AA, MARCHIORI PE: Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis. Arq. Neuropsiquiatr. (1999) 57(3A):683-685.
67. SANTOS JL, SWENSEN P, GLASGOW LA: Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics (1981) 68:50-54.
68. WANG YC, BURR DH, KORTHALS GJ, SUGIYAMA H: Acute toxicity of aminoglycoside antibiotics as an aid in detecting botulism. Appl. Environ. Microbiol. (1984) 48:951-955.
69. MOREL E, FEUILLET-FIEUX MN, VERNET-DER GARABEDIAN B et al.: Autoantibodies in D-penicillamine-induced myasthenia gravis: a comparison with idiopathic myasthenia and rheumatoid arthritis. Clin. Immunol. Immunopathol. (1991) 58:318-330.
70. KADIEVA V, VAN HEERDEN PV, ROUX A et al.: Neuromuscular blockade and ventilatory failure after cyclosporine. Can. J. Anaesth. (1992) 39:402-403.
71. COMELLA CL, TANNER CM, DEFOOR-HILL L, SMITH C: Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology (1992) 42:1307-1310.
72. GLANZMAN RL, GELB DJ, DRURY MB et al.: Brachial plexopathy after botulinum toxin injections. Neurology (1990) 43:1143.
73. VIEREGGE P, KOMPF D: Brachial plexopathy after botulinum toxin administration for cervical dystonia. J. Neurol. Neurosurg. Psychiatry (1993) 56:1338-1342.
74. MANN AC: Localized autonomic failure due to botulinum toxin injection. J. Neurol. Neuerosurg. Psych. (1994) 57:1320.
75. LATIMER PR, HODGKINS PR, VAKALIS AN, BUTLER RE, EVANS AR, ZAKI GA: Necrotizing fasciitis as a complication of botulinum toxin injection. Eye (1998) 12:51-53.
76. SANDERS DB, MASSEY EW, BUCKLEY EG: Botulinum toxin for blepharospasm: single fiber EMG studies. Neurology (1986) 36:545-547.
77. LANGE DI, BRIN MF, WARNER CI et al.: Distant effects of local injection of botulinum toxin. Muscle Nerve (1987) 10:552-555.
78. GIRLANDA P, VITA G, NICOLOSI C et al.: Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J. Neurol. Neurosurg. Psychiatry (1992) 55:844-845.
79. CLAUS D, DRUSCHKY A, ERBJUTH F: Botulinum toxin: influence on respiratory heart rate variation. Mov. Disord. (1995) 10:574-579.
80. MONTECUCCO C, SCHIAVO G, TUGNOLI V, DE GRANDIS D: Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol. Med. Today (1996) 2:418-424.